Clinical trials: Choroideremia
Alcohol Dependence
Cerebral Hemodynamics With rTMS in Alcohol Dependence
The present study measures the cerebral hemodynamic indices of alcohol dependent patients and observe the relative changes in these parameters with rTMS application.
- Trial name
- NCT02446067
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- India
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Central Institute of Psychiatry, Ranchi, India
Delirium
Cerebral Blood Flow During CPB During Cardiac Surgery and the Presence of Post op Delirium
Cardiac surgery is associated with multiple events and issues that increase risk for adverse postoperative neurological outcomes including postoperative cognitive dysfunction.
- Trial name
- NCT02084394
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Johns Hopkins University
Choroideremia
An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia
A project has been developed in Edmonton, Alberta, Canada to enable male patients with choroideremia to access a clinical trial that replaces the defective gene with a normal copy.
- Trial name
- NCT02077361
- Testing
- rAAV2.REP1 vector
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University of Alberta
Retinitis Pigmentosa, Cone-Rod Dystrophy
IRIS PILOT - Extended Pilot Study With a Retinal Implant System
Investigate whether blind subjects that fulfil the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross.
- Conditions
- Retinitis Pigmentosa, Cone-Rod Dystrophy, Choroideremia
- Trial name
- NCT00427180
- Testing
- Retinal Implant System (IRIS)
- Volunteers
- 20 people
- Sponsor
- Intelligent Medical Implants GmbH
Retinitis Pigmentosa, Choroideremia
Longitudinal Study of a Bionic Eye
This is a longitudinal observational study with participants who have been implanted with the suprachoroidal retinal prosthesis.
- Trial name
- NCT05158049
- Where
- Australia
- Volunteers
- 7 people
- Sponsor
- Center for Eye Research Australia
Retinitis Pigmentosa, Stargardt Disease 1
Structural and Functional Characterization of Rare Ocular Diseases
Rare ocular diseases (ROD) are a heterogeneous group of ocular diseases that affect very few people and, generally, for which no tretament is available. An important subgroup of these diseases are inherited retinal degenerations.
- Conditions
- Retinitis Pigmentosa, Stargardt Disease 1, Best Disease, Pattern Dystrophy of Macula
- Trial name
- RADIS (NCT05258032)
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Barcelona Macula Foundation
Choroideremia, CHM (Choroideremia) Gene Mutations
Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
This clinical study evaluates the safety and tolerability of AAV2-hCHM in participants with Choroideremia gene mutations.
- Trial name
- NCT02341807
- Testing
- AAV2-hCHM
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Spark Therapeutics, Inc.
Choroideremia
Natural History of the Progression of Choroideremia Study
The objective of this natural history study is to gain a better understanding of the progression of choroideremia (CHM) and add to the knowledge base for this rare disease.
- Trial name
- NIGHT (NCT03359551)
- Where
- 20 sites in United States, Brazil and 7 more
- Volunteers
- 319 people
- Sponsor
- NightstaRx Ltd, a Biogen Company
Choroideremia
The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia
Primary objective: To examine the short-term effects of of simvastatin on the vision on males with choroideremia, evaluated by full-field scotopic threshold testing.
- Trial name
- NCT01654562
- Testing
- Simvastatin
- Where
- Canada
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Retinitis Pigmentosa, Choroideremia
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
A phase I/II dose-escalating study of the safety, tolerability and efficacy of KIO-301 administered intravitreally to patients with retinitis pigmentosa and choroideremia (ABACUS).
- Conditions
- Retinitis Pigmentosa, Choroideremia, Non-Syndromic Rod-Dominant Inherited Retinal Diseases
- Trial name
- NCT05282953
- Testing
- KIO-301
- Where
- 3 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Choroideremia
A Study to Assess Choroideremia (CHM) Health Outcomes
The primary objectives of this study are to describe disease progression and severity by age in participants with CHM, to assess health-related quality-of-life, resource utilization and work productivity, and to assess…
- Trial name
- NCT04750785
- Testing
- No Intervention
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Biogen
Choroideremia
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
This study will evaluate safety, tolerability, and preliminary efficacy of a single intravitreal (IVT) injection of a recombinant adeno-associated virus (AAV) gene therapy, 4D-110, in male patients with genetically-confirmed…
- Trial name
- NCT04483440
- Testing
- 4D-110
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- 4D Molecular Therapeutics
Choroideremia
"Natural History" Study of Choroideremia
The purpose of this study is to understand the rate of progression of all stages of choroideremia using a variety of assessments performed in the clinic including visual field measures, specialized photography of the eye and…
- Trial name
- NCT02994368
- Testing
- Observation
- Where
- 4 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- 4D Molecular Therapeutics
Choroideremia
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
The objective of the study is to evaluate the safety of bilateral, sequential sub-retinal administration of a single dose of BIIB111 in adult male participants with Choroideremia (CHM).
- Trial name
- GEMINI (NCT03507686)
- Testing
- BIIB111
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 66 people
- Sponsor
- Biogen
Stroke
Effects of Aerobic Exercise on the Cerebral Arterial System, Cognitive, and Motor Function in Post-stroke Patients.
Background: Stroke is the second leading cause of death and disability worldwide and in Hong Kong, 6.2% of all registered deaths in 2020 were due to cerebrovascular disease.
- Trial name
- NCT05706168
- Testing
- treadmill exercise, Cycle ergometer exercise
- Where
- Hong Kong
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Retinitis Pigmentosa, Cone Rod Dystrophy
Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy
This study evaluates the safety and effectiveness of the Intelligent Retinal Implants System (IRIS V2). Blind patient suffering from Retinitis Pigmentosa, Cone Rod Dystrophy, or Choroideremia are implanted with an Intelligent…
- Conditions
- Retinitis Pigmentosa, Cone Rod Dystrophy, Choroideremia
- Trial name
- IRIS 2 (NCT02670980)
- Testing
- Intelligent Retinal Implant System
- Where
- 9 sites in Austria, France and 3 more
- Volunteers
- 10 people
- Sponsor
- Science Corporation
Choroideremia
The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study
Choroideremia (CHM) is an inherited retinal disorder that causes progressive vision loss, ultimately leading to complete blindness.
- Trial name
- DARC (NCT05045703)
- Testing
- Vitamin A palmitate
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Duke University
Choroideremia
Gene Therapy for Blindness Caused by Choroideremia
Primary objective: To assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in 12 patients with a diagnosis of choroideremia.
- Trial name
- NCT01461213
- Testing
- rAAV2.REP1
- Where
- 4 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- University of Oxford
Retinitis Pigmentosa, Choroideremia
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015.
- Trial name
- NCT06460844
- Testing
- RTx-015
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ray Therapeutics, Inc.
Choroideremia
Natural Disease Progression in Participants With Choroideremia
The primary objective of this study is to quantify disease progression measured by best corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM) participants.
- Trial name
- NCT04795206
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 1,178 people
- Sponsor
- Biogen